Pharmacopoeial HPLC methodology improvement: A case study of piroxicam

Mikaelly P. Caet; Millena A. Monsores; Anna Karolina M. S. Machado; Thiago Barth; Maximiliano S. Sangoi; Vítor Todeschini

doi:10.22456/2527-2616.108512

Authors

Mikaelly P. Caet Curso de Farmácia - Universidade Federal do Rio de Janeiro
Millena A. Monsores Curso de Farmácia - Universidade Federal do Rio de Janeiro
Anna Karolina M. S. Machado Programa de Pós-graduação em Produtos Bioativos e Biociências - Curso de Farmácia - Universidade Federal do Rio de Janeiro
Thiago Barth Programa de Pós-graduação em Produtos Bioativos e Biociências - Curso de Farmácia - Universidade Federal do Rio de Janeiro
Maximiliano S. Sangoi Programa de Pós-graduação em Produtos Bioativos e Biociências - Curso de Farmácia - Universidade Federal do Rio de Janeiro
Vítor Todeschini Curso de Farmácia - Universidade Federal do Rio de Janeiro

DOI:

https://doi.org/10.22456/2527-2616.108512

Keywords:

method improvement, piroxicam, high performance liquid chromatography, validation

Abstract

In the present study, a simple, stability-indicating and cost-effective reversed-phase high performance liquid chromatography (HPLC) method was developed and validated for the determination of piroxicam in commercial and masterful formulation capsules as an alternative to existing methods. The improved HPLC method was carried out on a C18 column (150 mm x 4.6 mm i.d., 5 μm), maintained at 30 °C. The mobile-phase consisted of a solution of triethylamine 0.3% pH 5.0 and acetonitrile (70:30; v/v), run at a flow rate of 1.0 mL/min and using photodiode array (PDA) detection at 248 nm. The chromatographic separation is obtained with retention time of 6.8 min, presenting adequate system suitability parameters for HPLC analysis. Validation parameters such as the specificity, linearity, matrix effect, precision, accuracy and robustness were evaluated in accordance with the ICH Q2(R1) and Brazil RDC 166/17 requirements, giving satisfactory results within the acceptable range. The proposed method was successfully validated and applied for piroxicam analysis, contributing to improve the quality control, and can be used as easy, accurate, low time-consuming alternative to pharmacopeial quantification methodology of drug.

Downloads

Download data is not yet available.

References

Brazilian Pharmacopeia. 6th. Edition. Brazilian Health Regulatory, 2019.

United States Pharmacopeia. USP 43–NF 38. Rockville: The United States Pharmacopoeial Convention, 2020.

Richards JA, Cole DA, Hickey RJ, Sokol LS. High performance liquid chromatography assay for piroxicam in pharmaceutical products. J Chromatogr Sci. 1987; 25(7): 292-295.

Bartsch H, Eiper A, Kopelent-Frank H. Stability indicating assays for the determination of piroxicamcomparison of methods. J Pharm Biomed Anal. 1999; 20(3): 531-541.

Basan H, Goger NG, Ertas N, Orbey MT. Quantitative determination of piroxicam in a new formulation (piroxicam-β-cyclodextrin) by derivative UV spectrophotometric method and HPLC. J Pharm Biomed Anal. 2001; 26(2): 171-178.

Savaser A, Karata A, Özkan Y, Yüksel N, Özkan SA, Baykara T. Validated LC determination of the piroxicam-β-cyclodextrin inclusion complex in tablets and in human plasma. Chromatographia. 2004; 59: 555- 560.

Kurakula M, Mohd AB, Rao PA, Diwan PV. Estimation of piroxicam in proliposomal formulation using RP HPLC method. Int J Chem Anal Sci. 2011; 2(9): 1193- 1196.

Abdulkarim MF, Abdullah GZ, Sakeena MHF, Chitneni M, Yam MF, Mahdi ES, et al. Modification and validation of an HPLC method for quantification of piroxicam. Int J Drug Deliv. 2011; 3(1): 51-54.

Khan IU, Ashfaq M, Razzaq SN, Mariam I. Simultaneous determination of piroxicam and paracetamol in pharmaceutical formulations using stability indicating HPLC method. J Liq Chromatogr R T. 2013; 36(10): 1437-1450.

John P, Azeem W, Ashfaq M, Khan IU, Razzaq SN. Stability indicating RP-HPLC method for simultaneous determination of piroxicam and ofloxacin in binary combination. Pak J Pharm Sci. 2015; 28(5): 1713-1721.

Dragomiroiu G, Cimpoieşu A, Ginghina O, Baloescu C, Barca M, Popa DE, et al. The development and validation of a rapid HPLC method for determination of piroxicam. Farmacia. 2015; 63: 123-131.

Fenner H. Comparative biochemical pharmacology of the oxicams. Scand J Rheumatol. 1987; 65: 97-101.

Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal antiinflammatory agents. Clin Pharmacokinet. 1994; 26(2): 107-120.

Parisotto G, Souza JS, Ferrão MF, Furtado JC, Molz RF. Análise exploratória aplicada no estudo de medicamentos contendo piroxicam. Rev Bras Cienc Farmac. 2005; 41(4): 499-505.

Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of NSAIDs and beyond. IUBMB Life. 2014; 66(12): 803-811.

Pulpeiro OG, Pérez YS, Mishing M, Thanh TD. Desarrollo y optimización de una jalea de piroxicam 0,5%. Rev Cuba Farm. 2009; 43(4): 4-19.

Littlejohn EA, Monrad SU. Early diagnosis and treatment of rheumatoid arthritis. Prim Care Clin Office Pract. 2018; 45: 237-255.

Jug M, Laćan MB, Kwokal A, Čižmek BC. Influence of cyclodextrin complexation on piroxicam gel formulations. Acta Pharm. 2005; 55: 223-36.

Amorim SR, Klier AH, Angelis LH. Controle de qualidade na indústria farmacêutica: identificação de substâncias por espectroscopia no infravermelho. Braz J Pharm. 2013; 94(3): 234-242.

Shaaban H. New insights into liquid chromatography for more eco-friendly analysis of pharmaceuticals. Anal Bioanal Chem. 2016; 408(25): 6929-6944.

International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceutical for Human Use. Validation of Analytical Procedures: Text and Methodology Q2(R1). Geneva, Switzerland, 2005. 17p.

Agência Nacional de Vigilância Sanitária (Anvisa). Resolução RDC n° 166 de 27 de julho de 2017. Dispõe sobre a validação de métodos analíticos e dá outras providências. Brasília, Brazil: Diário Oficial da União; 2017.

Bakshi M, Singh S. Development of validated stability-indicating assay methods-critical review. J Pharm Biomed Anal. 2002; 28(6): 1011-1040.

Holm R, Elder DP. Analytical advances in pharmaceutical impurity profiling. Eur J Pharm Sci. 2016; 87: 118-135.

Ramachandra B. Development of impurity profiling methods using modern analytical techniques. Crit Rev Anal Chem. 2017; 47(1): 24-36.

Food and Drug Administration (FDA). Reviewer Guidance: Validation of Chromatographic Methods. Silver Spring, USA, 1994. 33p.

Aszyk J, Kot J, Tkachenko Y, Woźniak M, BoguckaKocka A, Kot-Wasik A. Novel liquid chromatography method based on linear weighted regression for the fast determination of isoprostane isomers in plasma samples using sensitive tandem mass spectrometry detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1051: 17-23.

Srinubabu G, Raju CAI, Sarath N, Kumar PK, Rao JVLN. Development and validation of a HPLC method for the determination of voriconazole in pharmaceutical formulation using an experimental design. Talanta. 2007; 71(3): 1424-1429.

Sangoi MS, Todeschini V, Steppe M. Determination of fesoterodine in a pharmaceutical preparation by a stability-indicating capillary zone electrophoresis method. J AOAC Int. 2013; 96(6): 1308-1314.

Vanaja K, Rani RHS. Design of experiments: concept and applications of Plackett-Burman design. Clin Res Regul Aff. 2007; 24(1): 1-23.

Sangoi MS, Todeschini V, Steppe M. Fesoterodine stress degradation behavior by liquid chromatography coupled to ultraviolet detection and electrospray ionization mass spectrometry. Talanta. 2011; 84(4): 1068-1079.

Heyden, YV, Nijhuis A, Smeyers-Verbeke J, Vandeginste, BGM, Massart DL. Guidance for robustness/ruggedness tests in method validation. J Pharm Biomed Anal. 2001; 24(5-6): 723-753.